PharmaCyte Biotech Inc (PMCB)

[The Giant]

So, what you are saying is that there is validation for a cell-in-a-box type product because another company is also testing its viability via clinical trials? You could argue that you need to be first to market in biopharma, but there is no guarantee the competitive offering is as effective or will receive approval (same with NVLX). Just because a competitor exists is by no means a bad thing...market validation is important. You just need to back the right horse and I'm backing NVLX.